Trial Information
H-8577:Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
Inclusion Criteria:
- Subject has a histologically confirmed diagnosis of superficial or muscle-invasive
bladder cancer
- Subject is a Texas resident.
- Subject can understand English or a qualified translator is available for the
interview.
- Subjects of any age, gender, or ethnicity are eligible to participate in the study.
- Subject consents to participate in the study.
Exclusion Criteria:
- Subject has had prior treatment with systemic chemotherapy or radiotherapy in the
past 6 months.
- Subject has been diagnosed with superficial or muscle-invasive bladder cancer more
than twelve months ago.
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
To assess both cohorts, two mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen.
Outcome Time Frame:
After last subject has completed the study
Safety Issue:
No
Principal Investigator
Seth P. Lerner, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Baylor College of Medicine
Authority:
United States: Institutional Review Board
Study ID:
H-8577
NCT ID:
NCT00848289
Start Date:
July 2008
Completion Date:
January 2014
Related Keywords:
- Bladder Cancer
- Healthy
- Bladder cancer
- Genetic susceptibility
- Increased Risk
- Urinary Bladder Neoplasms
- Disease Susceptibility
Name | Location |
Baylor College of Medicine |
Houston, Texas 77030 |
M.D. Anderson Cancer Center |
Houston, Texas 77030 |